Pfizer CEO expects COVID vaccine trials for kids to be completed in September


The Pfizer-BioNTech COVID-19 vaccine was fully approved on Monday by the Food and Drug Administration for people 16 and older, but it will still be some time before it's authorized for use in young children.
The Pfizer vaccine is available for kids between the ages of 12 and 15 under an emergency use authorization. Before emergency use authorization can be expanded to kids under 12 — which is expected this fall or winter, NBC News reports — clinical trials must be completed. Dr. Peter Marks, director of the FDA's Center for Biologics Evaluation and Research, told reporters on Monday the agency needs to have a "good safety dataset, because we certainly want to make sure we get it right in the children ages 5 through 11 and then even in younger children after that."
Pfizer and Moderna are both conducting vaccine trials in kids to determine the proper dosage and whether it is safe and effective for younger people. Pfizer CEO Albert Bourla told NBC News on Monday he expects studies on children ages 5 to 11 will finish in September, and the data will then get submitted to the FDA. Following adult vaccine trials, the FDA asks for two months worth of follow-up safety data, but for the children's trials, the FDA is requesting four to six months of data.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
In the week ending last Thursday, there were 180,000 new cases of COVID-19 among kids and teenagers, the American Academy of Pediatrics said in a statement on Monday, and the organization is urging the FDA to "work aggressively to authorize a vaccine for ages 11 and younger."
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Catherine Garcia has worked as a senior writer at The Week since 2014. Her writing and reporting have appeared in Entertainment Weekly, The New York Times, Wirecutter, NBC News and "The Book of Jezebel," among others. She's a graduate of the University of Redlands and the Columbia University Graduate School of Journalism.
-
The week's best photos
In Pictures A tomato fight, painting behind bars, and more
-
Mountainhead: Jesse Armstrong's tech bro satire sparkles with 'weapons-grade zingers'
The Week Recommends The Succession creator's first feature film lacks the hit TV show's 'dramatic richness' – but makes for a horribly gripping watch
-
Seeing Each Other: Portraits of Artists – a 'riveting' exhibition
The Week Recommends Pallant House exhibition offers fascinating instances of painterly reciprocity
-
Breakthrough gene-editing treatment saves baby
speed read KJ Muldoon was healed from a rare genetic condition
-
Sea lion proves animals can keep a beat
speed read A sea lion named Ronan beat a group of college students in a rhythmic dance-off, says new study
-
Humans heal much slower than other mammals
Speed Read Slower healing may have been an evolutionary trade-off when we shed fur for sweat glands
-
Novel 'bone collector' caterpillar wears its prey
Speed Read Hawaiian scientists discover a carnivorous caterpillar that decorates its shell with the body parts of dead insects
-
Scientists find hint of alien life on distant world
Speed Read NASA's James Webb Space Telescope has detected a possible signature of life on planet K2-18b
-
Katy Perry, Gayle King visit space on Bezos rocket
Speed Read Six well-known women went into lower orbit for 11 minutes
-
Scientists map miles of wiring in mouse brain
Speed Read Researchers have created the 'largest and most detailed wiring diagram of a mammalian brain to date,' said Nature
-
Scientists genetically revive extinct 'dire wolves'
Speed Read A 'de-extinction' company has revived the species made popular by HBO's 'Game of Thrones'